|  |  |  |
| --- | --- | --- |
|  |  |  |
| 5D | 10 | Female common |
| 5D (HD) | 28 | Male more likely to progress |
| 5D (HD) | 43 | Neutral |
| 5D (HD) | 207 | Male common and more severe |
| 5D | 112 | Neutral |
| 5D (HD) | 423 | Male common and more severe |
| 5D | 143 | Neutral |
| 5D (HD) | 141 | Neutral |
| 2-4 | 3404 | Neutral |
| 5D | 90 | Neutral |
| 5D (HD) | 289 | Neutral |
| 5D (HD) | 96 | Neutral |
| 5D (HD) | 88 | Neutral |
| 5D (HD) | 303 | Male more severe |
| 5D, 5T | 240 | Neutral |
| 1-4 | 1541 | Male more severe |
| Proteinuric (1-5) | 225 | Neutral |
| 5D (HD) | 97 | Male more likely to progresses |
| 3 | 120 | Male common |
| 5T | 115 | Neutral |
| 5D (HD) | 132 | Male more severe |
| 5D | 232 | Male more common |
| 3-4 | 178 | Male more severe |
| 5T | 131 | Neutral |
| 5T | 112 | Neutral |
| 4-5, 5D | 44 | Male more severe |
| 2-5D, 5T | 419 | Female more severe (subgroup) |
| 5D (HD) | 49 | More male with CAC |
| 4-5 | 95 | Neutral |
| 5D (HD) | 132 | Neutral |
| 5 | 172 | Neutral |
| 5D (HD) | 60 | Neutral |
| 2-5 | 117 | Male more severe |
| 5D (HD) | 150 | Neutral |
| 2-4 | 2018 | Male more severe |
| 5D (HD) | 120 | Neutral |
| 5D | 129 | Neutral |
| 5D (HD) | 90 | Male common |
| 5D (HD) | 90 | Male gender |
| 3-4 | 84 | Neutral |
| 5D (HD) | 227 | Neutral |
| 5D (HD) | 161 | Male more severe |
| 5D (HD) | 85 | Neutral |
| 3 | 139 | Male more common |
| 5T | 205 | Male more severe, segment-specific |
| 5T | 699 | Neutral |
| 5D | 47 | Neutral |
| 5D | 184 | Neutral |
| 5D (HD) | 137 | Male more common early during lifetime |
| 5D (HD) | 301 | Female common |
| 5D (HD) | 712 | Neutral |
| 5D (HD) | 61 | Neutral |
| 2-5 | 1078 | Male more common |
| 3b-4 | 278 | Male more common |
| 5D | 41 | Neutral |
| 5D (HD) | 32 | Neutral |
| 5D (HD) | 155 | Neutral |
| 5, 5D, 5T | 73 | Neutral |
| 5D, 5T | 100 | Male more severe |
| 3-5 | 32 | Male more severe |
| 5T | 50 | Neutral |
| 2-5 | 145 | Neutral |
| 1-5 | 133 | Male common |
| 5T | 119 | Neutral |
| 5D (HD) | 216 | Female more severe |
| 5D (PD) | 150 | Neutral |
| 5D (HD) | 56 | Neutral |
| 5D (HD) | 184 | Male more likely to worsen |
| 5D (HD) | 80 | Neutral |
| 5T | 89 | Male more severe |
| 5D (HD) | 144 | Neutral |
| 5D (HD) | 24 | Male more likely to worsen |
| 5D (HD) | 92 | Neutral |
| 5D (HD) | 45 | Neutral |
| 5D (HD) | 212 | Male common |
| 5T | 99 | Male more severe |
| 4-5D | 134 | Male more severe |
| 5D (HD) | 65 | Neutral |
| 5D (PD) | 24 | Male gender (%) |
| 2-4 | 50 | Male more common |
| 5D (HD) | 224 | Male more severe |
| 3-5 | 300 | Male more severe |
| 5D (PD) | 192 | Neutral |
| 5D (PD) | 190 | Neutral |
| 5D (HD) | 134 | Male more common |
| 1-5 | 151 | Male more common |
| 2-3 | 2070 | Neutral |
| 5D (HD) | 123 | Male more severe |
| 2-4 | 1274 | Neutral |
| 1-5 | 1832 | Neutral |
| 5T | 115 | Neutral |
| 5 | 152 | Male more severe |
| 5D (HD) | 360 | Neutral |
| 5D (HD) | 150 | Male more common, especially intimal |
| 3-5 | 562 | Male more common |
| 5D (HD) | 309 | Female more common |
| 5T | 197 | Male more likely to worsen |
| 5D (HD) | 81 | Neutral |
| 5D (HD) | 148 | Neutral |
| 3-4 | 112 | Male more common |
| 5D (HD) | 108 | Neutral |
| 5D (HD) | 77 | Male more common |